Apellis Pharmaceuticals Q3 EPS $(1.17) Misses $(0.85) Estimate, Sales $110.40M Beat $99.74M Estimate
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals reported Q3 losses of $(1.17) per share, missing the analyst consensus estimate of $(0.85) by 37.65%. However, the company's quarterly sales of $110.40 million beat the analyst consensus estimate of $99.74 million by 10.69%. This represents a 400.54% increase over sales of $22.06 million the same period last year.
November 01, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Apellis Pharmaceuticals reported a larger than expected Q3 loss but beat sales estimates. This mixed result could lead to volatility in the stock's price.
While Apellis Pharmaceuticals missed its Q3 earnings per share estimate, it exceeded sales expectations. This mixed result could lead to uncertainty and volatility in the stock's price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100